secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2021-12-09T23:59:59+00:00
Accession:  0001104659-21-147869
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada reports Q3 2021 net loss $14.4M and closes $208.7M IPO
--------------------------------------------------------------

- Net loss for Q3 2021 was $14.4M vs $7.0M in Q3 2020; R&D expense $10.5M, G&A $3.9M.
- Closed upsized IPO in November, raising $208.7M gross ($190.9M net) at $20.00 per share.
- IPO included full exercise of underwriters' option for 1.36M additional shares; total shares issued 10.44M.
- Cash position as of Sep 30, 2021 was $122.2M, excluding IPO proceeds; post-IPO cash significantly strengthened.
- Lead candidate ENTR-601-44 for DMD advancing toward initial clinical data; DM1 program entering development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000110465921147869/0001104659-21-147869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000110465921147869/tm2134805d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-147869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer